Cadrenal Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is CVKD moving today?
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CVKD.
CVKD insider activity
Cadrenal Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for CVKD.
CVKD contract awards, year to date.
Public federal awards linked to this ticker.
CVKD lobbying filings, year to date.
Registered lobbying filings matched to Cadrenal Therapeutics, Inc. Common Stock.